Compare Stocks: TARS, CORT, ELAN, and AXSM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$206.68 -0.8%	$223.81	$112.90 ▼ $260.19	$10.91B	0.71	669,213 shs	438,239 shs
CORT Corcept Therapeutics	$111.62 -1.0%	$104.13	$28.66 ▼ $126.38	$12.19B	0.45	818,149 shs	602,698 shs
ELAN Elanco Animal Health	$24.48 +0.2%	$24.64	$17.51 ▼ $27.98	$12.24B	1.68	7.17 million shs	3.72 million shs
TARS Tarsus Pharmaceuticals	$90.78 +9.1%	$66.01	$48.20 ▼ $91.53	$3.98B	0.54	743,029 shs	1.60 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-0.80%	+3.85%	-2.90%	-11.04%	+69.41%
CORT Corcept Therapeutics	-1.05%	-1.98%	+0.84%	+53.70%	+56.46%
ELAN Elanco Animal Health	+0.29%	+1.32%	-6.55%	+3.68%	+41.18%
TARS Tarsus Pharmaceuticals	+9.10%	+26.51%	+48.12%	+53.14%	+57.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$206.68 -0.8%	$223.81	$112.90 ▼ $260.19	$10.91B	0.71	669,213 shs	438,239 shs
CORT Corcept Therapeutics	$111.62 -1.0%	$104.13	$28.66 ▼ $126.38	$12.19B	0.45	818,149 shs	602,698 shs
ELAN Elanco Animal Health	$24.48 +0.2%	$24.64	$17.51 ▼ $27.98	$12.24B	1.68	7.17 million shs	3.72 million shs
TARS Tarsus Pharmaceuticals	$90.78 +9.1%	$66.01	$48.20 ▼ $91.53	$3.98B	0.54	743,029 shs	1.60 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-0.80%	+3.85%	-2.90%	-11.04%	+69.41%
CORT Corcept Therapeutics	-1.05%	-1.98%	+0.84%	+53.70%	+56.46%
ELAN Elanco Animal Health	+0.29%	+1.32%	-6.55%	+3.68%	+41.18%
TARS Tarsus Pharmaceuticals	+9.10%	+26.51%	+48.12%	+53.14%	+57.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	2.91	Moderate Buy	$267.60	29.48% Upside
CORT Corcept Therapeutics	2.50	Moderate Buy	$138.17	23.78% Upside
ELAN Elanco Animal Health	2.77	Moderate Buy	$29.09	18.84% Upside
TARS Tarsus Pharmaceuticals	2.90	Moderate Buy	$90.50	-0.31% Downside

Current Analyst Ratings Breakdown

Latest TARS, CORT, ELAN, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	TARS Tarsus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/31/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$290.00
8/24/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/24/2026	AXSM Axsome Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	CORT Corcept Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/20/2026	ELAN Elanco Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/18/2026	CORT Corcept Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$164.00
8/18/2026	AXSM Axsome Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$97.00 ➝ $100.00
8/12/2026	AXSM Axsome Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$306.00 ➝ $316.00
8/11/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$304.00 ➝ $297.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$776.57M	13.94	N/A	N/A	$1.59 per share	129.99
CORT Corcept Therapeutics	$761.41M	15.85	$0.89 per share	124.95	$6.53 per share	17.09
ELAN Elanco Animal Health	$5.02B	2.44	$2.33 per share	10.52	$13.19 per share	1.86
TARS Tarsus Pharmaceuticals	$606.33M	6.57	N/A	N/A	$7.90 per share	11.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$183.17M	-$3.75	N/A	50.91	N/A	-24.68%	-265.55%	-28.10%	11/2/2026 (Estimated)
CORT Corcept Therapeutics	$99.65M	$0.42	265.77	32.45	N/A	6.52%	8.26%	6.45%	11/4/2026 (Estimated)
ELAN Elanco Animal Health	-$232M	-$0.41	N/A	19.28	1.82	-3.96%	8.13%	3.99%	11/4/2026 (Estimated)
TARS Tarsus Pharmaceuticals	-$66.42M	-$1.09	N/A	159.26	N/A	-7.67%	-13.53%	-8.12%	11/3/2026 (Estimated)

Latest TARS, CORT, ELAN, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8921	-$0.99	-$0.0980	-$0.99	$221.11 million	$218.38 million
8/6/2026	Q2 2026	TARS Tarsus Pharmaceuticals	-$0.1918	-$0.43	-$0.2382	-$0.43	$169.65 million	$173.91 million
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.2692	$0.34	+$0.0708	$0.11	$1.31 billion	$1.37 billion
7/29/2026	Q2 2026	CORT Corcept Therapeutics	$0.0243	$0.36	+$0.3357	$0.36	$221.15 million	$256.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.52	1.43	1.34
CORT Corcept Therapeutics	N/A	2.86	2.77
ELAN Elanco Animal Health	0.58	2.05	1.10
TARS Tarsus Pharmaceuticals	0.21	3.20	3.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
CORT Corcept Therapeutics	93.61%
ELAN Elanco Animal Health	97.48%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	20.60%
CORT Corcept Therapeutics	20.70%
ELAN Elanco Animal Health	1.14%
TARS Tarsus Pharmaceuticals	9.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	52.38 million	41.59 million	Optionable
CORT Corcept Therapeutics	300	108.10 million	85.72 million	Optionable
ELAN Elanco Animal Health	9,400	499.62 million	493.93 million	Optionable
TARS Tarsus Pharmaceuticals	50	43.88 million	39.65 million	Optionable

TARS, CORT, ELAN, and AXSM Headlines

Recent News About These Companies

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Upgraded by Jefferies Financial Group

September 5 at 7:59 AM | marketbeat.com

Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition

September 4 at 8:35 PM | marketscreener.comM

Tarsus Pharmaceuticals Closes Acquisition of Alkeus Pharmaceuticals

September 4 at 3:35 PM | finance.yahoo.com

Tarsus Pharmaceuticals Completes Alkeus Acquisition; Adds Phase 3 Stargardt Disease Program

September 4 at 3:35 PM | rttnews.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 52-Week High - Should You Buy?

September 4 at 2:19 PM | marketbeat.com

Tarsus Pharmaceuticals Completes Acquisition of Alkeus, Adds Gildeuretinol for Stargardt Disease to Pipeline

September 4 at 8:51 AM | quiverquant.comQ

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

September 4 at 8:38 AM | globenewswire.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $339,829.86 in Stock

September 4 at 6:52 AM | insidertrades.com

114,458 Shares in Tarsus Pharmaceuticals, Inc. $TARS Bought by Bank of New York Mellon Corp

September 4 at 3:20 AM | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 4,601 Shares of Stock

September 3 at 5:07 PM | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 5,387 Shares

September 3 at 5:07 PM | marketbeat.com

Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease

September 3 at 11:10 AM | globenewswire.com

The Manufacturers Life Insurance Company Takes Position in Tarsus Pharmaceuticals, Inc. $TARS

September 3 at 4:32 AM | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 6.5% Higher - Should You Buy?

September 2 at 12:39 PM | marketbeat.com

Tarsus to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

Hsbc Holdings PLC Makes New $2.43 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS

August 31, 2026 | marketbeat.com

Canada Pension Plan Investment Board Acquires Shares of 98,900 Tarsus Pharmaceuticals, Inc. $TARS

August 31, 2026 | marketbeat.com

Freestone Grove Partners LP Takes Position in Tarsus Pharmaceuticals, Inc. $TARS

August 29, 2026 | marketbeat.com

Jefferies Financial Group Inc. Acquires New Position in Tarsus Pharmaceuticals, Inc. $TARS

August 28, 2026 | marketbeat.com

90,969 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Connor Clark & Lunn Investment Management Ltd.

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $7.91 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARS

August 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TARS, CORT, ELAN, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$206.68 -1.67 (-0.80%)

As of 09/4/2026 04:00 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corcept Therapeutics NASDAQ:CORT

$111.62 -1.18 (-1.05%)

As of 09/4/2026 04:00 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Elanco Animal Health NYSE:ELAN

$24.48 +0.06 (+0.25%)

As of 09/4/2026 03:58 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Tarsus Pharmaceuticals NASDAQ:TARS

$90.78 +7.57 (+9.10%)

As of 09/4/2026 04:00 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TARS, CORT, ELAN, and AXSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TARS, CORT, ELAN, and AXSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TARS, CORT, ELAN, and AXSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TARS, CORT, ELAN, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Corcept Therapeutics NASDAQ:CORT

Elanco Animal Health NYSE:ELAN

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TARS, CORT, ELAN, and AXSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TARS, CORT, ELAN, and AXSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TARS, CORT, ELAN, and AXSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TARS, CORT, ELAN, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Corcept Therapeutics NASDAQ:CORT

Elanco Animal Health NYSE:ELAN

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools